Home›Stock Screener›Bliss GVS Pharma

Bliss GVS Pharma Share Price Today | Stock Price & Bliss GVS Pharma Share Screener

BLISSGVS Pharmaceuticals
Live Share Price NSE
₹523.55
▼ -16.05 (-2.97%)
2026-07-01 00:00:00
Live Share Price BSE
₹660.45
▼ -23.75 (-3.47%)
2026-10-05 00:00:00

As of July 1, 2026, the live Bliss GVS Pharma share price (NSE: BLISSGVS) is ₹523.55 on NSE and ₹660.45 on BSE, down 2.97% from the previous close, with shares trading between ₹514.15 and ₹547.40 in today's trading session, and a 52-week range of ₹127.90–₹539.60. Check BLISSGVS price range for the annual price range and momentum. Use the Bliss GVS Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Bliss GVS Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹268 and net income of ₹37, with EBITDA of ₹56, an operating margin of 17.0% and a profit margin of 13.8%.

Bliss GVS Pharma Market Cap ₹7,264.97 Cr.
BLISSGVS P/E Ratio (TTM) 52.16
Bliss GVS Pharma P/B Ratio 6.20
EPS (TTM) ₹12.23
Dividend Yield 0.14%
Debt to Equity 0.05
BLISSGVS 52 Week High ₹539.60
Bliss GVS Pharma 52 Week Low ₹127.90
Operating Margin 17.00%
Profit Margin 13.81%
BLISSGVS Revenue (TTM) ₹268.00
EBITDA ₹56.00
Net Income ₹37.00
Total Assets ₹1,492.00
Total Equity ₹1,232.00

Bliss GVS Pharma Share Price Chart

Track the current stock price of Bliss GVS Pharma with an interactive chart. Analyse BLISSGVS share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Bliss GVS Pharma stock quote in one place.

The quote of ₹523.55 sits between the 52-week low of ₹127.90 and the 52-week high of ₹539.60, and the latest session moved -2.97% from the previous close.

Bliss GVS Pharma Company Profile - Fundamental Screener

Screen Bliss GVS Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BLISSGVS shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE416D01022.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE416D01022

Bliss GVS Pharma Balance Sheet Screener

Screen BLISSGVS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,492, up from ₹1,301 in 2025.

Latest statistics put total assets at ₹1,492 and shareholder funds at ₹1,232, with a leverage ratio of 0.05.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 1,492 1,301 1,212 1,157 1,109 1,077 1,027 905 860 1,023
Current Assets 946 824 811 697 777 765 770 694 690 566
Fixed Assets 459 406 370 379 282 234 242 146 143 305

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 25 37 51 46 29 45 46 38 13 33
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 1,232 1,092 1,003 917 847 828 750 660 548 553
Share Capital 11 11 11 10 10 10 10 10 10 10
Reserves & Surplus 1,182 1,040 957 874 808 798 725 636 526 476

Bliss GVS Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Bliss GVS Pharma income statement and profit fundamentals. Analyze BLISSGVS quarterly results. Bliss GVS Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹268 and net profit was ₹37, equal to earnings per unit of ₹3.37, at an operating margin of 17%.

In that period expenses were ₹213, interest cost ₹2 and tax ₹8. The next period listed, 2026-Jun, shows revenue of ₹295 and net profit of ₹51.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar

Revenue and Expenses

Revenue 268 295 210 243 253 237 204 188 223 226 188 165 225 206 179
Expenses 213 209 177 166 201 186 199 149 176 181 179 135 158 157 147

Operating Costs and Margins

EBITDA 56 86 33 77 52 51 5 39 47 45 9 29 67 49 32
Operating Profit % 17.00% 27.00% 11.00% 20.00% 18.00% 15.00% 0.00% 19.00% 19.00% 14.00% 3.00% 15.00% 26.00% 22.00% 12.00%
Depreciation 9 10 8 8 8 8 7 7 7 8 5 6 6 7 4
Interest 2 1 2 6 3 2 2 2 4 1 5 2 2 2 2

Profit and Earnings

Profit Before Tax 45 76 23 63 41 41 -4 30 36 36 -1 22 59 40 27
Tax 8 24 7 19 12 16 1 8 10 11 -4 7 16 11 3
Net Profit 37 51 17 44 29 25 -5 22 26 26 4 14 43 29 24
EPS 3.37 4.73 1.47 4.08 2.58 2.20 -0.88 1.97 2.31 2.27 0.34 1.41 4.06 2.64 1.90

Bliss GVS Pharma Cash Flow Screener - Liquidity Fundamentals

Screen BLISSGVS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹139, and net cash flow was an inflow of ₹11.

Over the same period, investing activities used ₹38 and financing activities used ₹89.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 139 106 103 34 136 64 47 40 18 290
Investing Activities -38 -76 -83 -6 -103 -45 -40 -79 48 -249

Financing and Net Cash

Financing Activities -89 -30 -21 -25 -24 -21 -6 17 -76 -10
Net Cash Flow 11 0 -1 3 9 -2 0 -22 -11 30

Bliss GVS Pharma Shareholding Pattern Screener

See Bliss GVS Pharma shareholding pattern with promoter, FII, and DII holdings. Check Bliss GVS Pharma promoter holding and ownership changes for BLISSGVS on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 35.36%, foreign institutions 10.45%, domestic institutions 5.04% and the public 32.60%, spread across 44,874 shareholders.

The shareholder count was 44,874 in 2026-Mar, compared with 46,767 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 35.36% 35.01% 35.29% 35.44% 35.39% 35.36% 34.97% 34.90%

Institutional Investors

FII Holding 10.45% 8.07% 13.18% 12.65% 13.27% 14.54% 14.73% 13.25%
DII Holding 5.04% 9.47% 6.55% 6.54% 5.98% 5.78% 6.59% 6.58%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 32.60% 29.77% 32.63% 32.79% 32.85% 31.48% 31.71% 32.84%
Other Holding 16.55% 17.68% 12.34% 12.58% 12.51% 12.84% 12.00% 12.43%
Shareholder Count 44,874 46,767 49,517 46,707 44,461 43,380 45,157 44,737

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Bliss GVS Pharma. Bliss GVS Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.50 per unit for 2026-March, a yield of 0.07%, compared with ₹0.50 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.50, ₹0.50 and ₹0.50 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.50 0.07%
2025-March ₹0.50 0.23%
2024-March ₹0.50 0.42%
2023-March ₹0.50 0.44%
2022-March ₹0.50 0.71%
2021-March ₹0.50 0.65%
2020-March ₹0.50 0.51%
2019-March ₹1.00 0.99%
2018-March ₹1.00 0.56%
2017-March ₹0.60 0.31%

Bliss GVS Pharma Stock Index Membership - Nifty & Sensex

See which indices include Bliss GVS Pharma stock. Check BLISSGVS index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 2 indices, including BSE INDEX BSE HC.

Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.

Complete Index List

BSE INDEX BSE HC
BSE INDEX SMLCAP

Bliss GVS Pharma Market Events Screener - Corporate Actions

Get Bliss GVS Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Bliss GVS Pharma stock events that may affect BLISSGVS share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 12, 2026, with a record date of August 12, 2026.

It is followed by Annual General Meeting dated July 15, 2026 and Dividend dated July 8, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-12 2026-08-12 Quarterly Result Announcement NA 1.04%
2026-07-15 2026-07-15 Annual General Meeting NA 91.48%
2026-07-08 2026-07-08 Dividend ₹ 1.00 /share 87.97%
2026-05-12 2026-05-12 Quarterly Result Announcement NA -0.82%
2026-02-18 2026-02-18 Dividend ₹ 0.50 /share 13.60%
2026-02-10 2026-02-10 Quarterly Result Announcement NA 17.93%
2025-11-06 2025-11-06 Quarterly Result Announcement NA 1.19%
2025-07-31 2025-07-31 Annual General Meeting NA 63.78%
2025-07-29 2025-07-29 Quarterly Result Announcement NA -4.19%
2025-07-24 2025-07-24 Dividend ₹ 0.50 /share 40.29%
2025-05-12 2025-05-12 Quarterly Result Announcement NA -5.06%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -13.24%
2024-10-24 2024-10-24 Quarterly Result Announcement NA -0.92%
2024-07-25 2024-07-25 Annual General Meeting NA -1.94%
2024-07-18 2024-07-19 Dividend ₹ 0.50 /share -9.96%

Bliss GVS Pharma Competitors Screener - Peer Stocks Comparison

Screen BLISSGVS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Bliss GVS Pharma Company Announcements - News & Reports Screener

Screen BLISSGVS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 4, 2026.

The next most recent announcements are dated October 3, 2026 and October 2, 2026.

Date Update Actions
2026-10-04 Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations") -
2026-10-03 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2026-10-02 Closure of Trading Window -
2026-10-01 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday October 01 2026 -
2026-10-01 Announcement under Regulation 30 (LODR)-Meeting Updates -
2026-10-01 Announcement under Regulation 30 (LODR)-Meeting Updates -
2026-10-01 Announcement under Regulation 30 (LODR)-Change in Management Control -
2026-09-22 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-09-22 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-09-04 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-09-02 Post-Offer Advertisement -
2026-08-25 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-21 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-20 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-08-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-12 Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019 -
2026-08-12 Outcome Of Board Meeting Held On Wednesday August 12 2026 -
2026-08-12 Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 12 2026 -
2026-08-11 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-08-11 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹523.55, within a 52-week range of ₹127.90 to ₹539.60. The P/E ratio is 52.16 and the P/B ratio is 6.20, with earnings per unit of ₹12.23. Market capitalisation stands at ₹7,264.97 Cr and the dividend yield is 0.14%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.